Amgen bought deCODE genetics for US$415 million in December 2012, with a plan to ramp up their use of human genetic data in drug discovery and development. This deal has since transformed Amgen's pipeline, says Amgen Chief Scientific Officer Sean Harper. A treasure trove of genetic data from more than 160,000 Icelanders now informs everything from target selection to clinical trial design. Genetic insights, sequencing capabilities and analytical expertise have helped the company to avoid costly failures, prosecute programmes more effectively and discover de novo drug targets, he told Asher Mullard.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Sean Harper. Nat Rev Drug Discov 17, 10–11 (2018). https://doi.org/10.1038/nrd.2017.262
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.262
